4 Healthcare Stock Stories Prescribed for Investors

Rosetta Genomics (NASDAQ:ROSG): Current price $4.48

Rosetta said that a manuscript in connection with the development and validation of its microRNA-based diagnostic assay for the classification of renal cell tumors has been accepted for publication by Molecular Oncology. Lead authors on the manuscript are Yael Spector, a scientist from Rosetta Genomics, and Dr. Eddie Fridman, a pathologist and an expert in urological pathology from the Isreali Sheba Medical Center in Tel-Hashomer. The company is a top developer and provider of microRNA-based molecular diagnostics.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ROSG